Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Cancer and Other Solid Tumors
NCT03924466Phase 2Recruiting
- Sponsor
- UZ Brussel
- Start
- Apr 2019
- Primary completion
- Nov 2024
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 2, open-label trial of [68Ga]Ga-NOTA-ABSCINT-HER2 in breast carcinoma and solid tumor (3 arms), sponsored by UZ Brussel. Primary endpoints: Repeatability of lesional PET/CT characteristics, Tracer uptake of 68GaNOTA-Anti-HER2 VHH1 in different cancer types and 1 more. Started Apr 2019; status: recruiting.
02
Drugs
[68Ga]Ga-NOTA-ABSCINT-HER2
03
Conditions
breast carcinomasolid tumor
Beyond the preview
Go deeper on NCT03924466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924466.